[go: up one dir, main page]

GB201615910D0 - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
GB201615910D0
GB201615910D0 GBGB1615910.5A GB201615910A GB201615910D0 GB 201615910 D0 GB201615910 D0 GB 201615910D0 GB 201615910 A GB201615910 A GB 201615910A GB 201615910 D0 GB201615910 D0 GB 201615910D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1615910.5A
Other versions
GB2554089A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mexichem Fluor SA de CV
Original Assignee
Mexichem Fluor SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mexichem Fluor SA de CV filed Critical Mexichem Fluor SA de CV
Priority to GB1615910.5A priority Critical patent/GB2554089A/en
Publication of GB201615910D0 publication Critical patent/GB201615910D0/en
Priority to CN202110262649.0A priority patent/CN113288869A/en
Priority to EP17777634.1A priority patent/EP3515441B1/en
Priority to JP2019515269A priority patent/JP6781830B2/en
Priority to CN201780057065.1A priority patent/CN109715160A/en
Priority to PCT/GB2017/052757 priority patent/WO2018051128A1/en
Priority to ES21183138T priority patent/ES2949975T3/en
Priority to EP21183138.3A priority patent/EP3909582B1/en
Priority to BR112019005080-9A priority patent/BR112019005080B1/en
Priority to MX2019003105A priority patent/MX387725B/en
Priority to CN202310227306.XA priority patent/CN116270640A/en
Priority to AU2017328905A priority patent/AU2017328905C1/en
Priority to ES17777634T priority patent/ES2891579T3/en
Priority to US16/334,151 priority patent/US11260052B2/en
Priority to CA3037080A priority patent/CA3037080C/en
Publication of GB2554089A publication Critical patent/GB2554089A/en
Priority to MX2021010022A priority patent/MX2021010022A/en
Priority to AU2020202580A priority patent/AU2020202580B2/en
Priority to JP2020140692A priority patent/JP6972256B2/en
Priority to US17/577,824 priority patent/US20220133709A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/124Aerosols; Foams characterised by the propellant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
GB1615910.5A 2016-09-19 2016-09-19 Pharmaceutical composition Withdrawn GB2554089A (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GB1615910.5A GB2554089A (en) 2016-09-19 2016-09-19 Pharmaceutical composition
CA3037080A CA3037080C (en) 2016-09-19 2017-09-18 Stable pharmaceutical compositions comprising indacaterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
BR112019005080-9A BR112019005080B1 (en) 2016-09-19 2017-09-18 PHARMACEUTICAL COMPOSITION, METERED-DOSE INHALER, AND METHODS FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION, FOR INCREASING THE STABILIZATION TIME OF A PHARMACEUTICAL COMPOSITION AND FOR IMPROVING THE AEROSOLIZATION PERFORMANCE OF A PHARMACEUTICAL COMPOSITION
CN202310227306.XA CN116270640A (en) 2016-09-19 2017-09-18 Pharmaceutical composition
JP2019515269A JP6781830B2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
CN201780057065.1A CN109715160A (en) 2016-09-19 2017-09-18 Pharmaceutical composition
PCT/GB2017/052757 WO2018051128A1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
ES21183138T ES2949975T3 (en) 2016-09-19 2017-09-18 Pharmaceutical composition comprising indacaterol
EP21183138.3A EP3909582B1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition comprising indacaterol
CN202110262649.0A CN113288869A (en) 2016-09-19 2017-09-18 Pharmaceutical composition
MX2019003105A MX387725B (en) 2016-09-19 2017-09-18 PHARMACEUTICAL COMPOSITION.
EP17777634.1A EP3515441B1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition comprising indacaterol
AU2017328905A AU2017328905C1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
ES17777634T ES2891579T3 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
US16/334,151 US11260052B2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
MX2021010022A MX2021010022A (en) 2016-09-19 2019-03-15 Pharmaceutical composition.
AU2020202580A AU2020202580B2 (en) 2016-09-19 2020-04-16 Pharmaceutical composition
JP2020140692A JP6972256B2 (en) 2016-09-19 2020-08-24 Pharmaceutical composition
US17/577,824 US20220133709A1 (en) 2016-09-19 2022-01-18 Pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1615910.5A GB2554089A (en) 2016-09-19 2016-09-19 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
GB201615910D0 true GB201615910D0 (en) 2016-11-02
GB2554089A GB2554089A (en) 2018-03-28

Family

ID=57288853

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1615910.5A Withdrawn GB2554089A (en) 2016-09-19 2016-09-19 Pharmaceutical composition

Country Status (1)

Country Link
GB (1) GB2554089A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112051346A (en) * 2020-09-24 2020-12-08 珠海瑞思普利生物制药有限公司 HPLC method for simultaneously determining content of indacaterol and glycopyrronium bromide

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2584686A (en) * 2019-06-11 2020-12-16 Mexichem Fluor Sa De Cv Methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505717A (en) * 2011-02-17 2014-03-06 シプラ・リミテッド Pharmaceutical composition
GB201306984D0 (en) * 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112051346A (en) * 2020-09-24 2020-12-08 珠海瑞思普利生物制药有限公司 HPLC method for simultaneously determining content of indacaterol and glycopyrronium bromide

Also Published As

Publication number Publication date
GB2554089A (en) 2018-03-28

Similar Documents

Publication Publication Date Title
IL265260B (en) Pharmaceutical composition
IL265360B (en) Pharmaceutical composition
IL262654A (en) Pharmaceutical composition
IL271986B1 (en) Pharmaceutical composition
IL265349A (en) Pharmaceutical composition
GB201712159D0 (en) Pharmaceutical composition
GB201521462D0 (en) Pharmaceutical composition
HUE068810T2 (en) Pharmaceutical composition
IL272419A (en) Pharmaceutical composition
GB201719447D0 (en) Pharmaceutical composition
IL263040A (en) Pharmaceutical composition comprising eteplirsen
PL3646867T3 (en) Pharmaceutical composition
PL3454838T3 (en) Pharmaceutical composition
GB201615917D0 (en) Pharmaceutical composition
GB201515310D0 (en) Pharmaceutical composition
GB201615914D0 (en) Pharmaceutical composition
GB201520862D0 (en) Pharmaceutical composition
IL263999A (en) Pharmaceutical compositions
GB201615910D0 (en) Pharmaceutical composition
IL265436B (en) Pharmaceutical composition
ZA201705782B (en) Pharmaceutical compositions
PL3424500T3 (en) Pharmaceutical composition comprising famitinib
GB201620519D0 (en) Pharmaceutical composition
IL265428A (en) Pharmaceutical composition
PT3476391T (en) Pharmaceutical composition

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)